Abstract:An in situ nanovaccine based on a cationic peptide with cholesterol‐modified, DP7‐C, for cancer immunotherapy is rationally designed, and develop a cancer nanovaccine that is easy to preparate. The nanovaccine includes cocktail small interfering RNAs (siRNAs) and immunologic adjuvant CpG ODNs, has synergistic effect in the cancer treatment. This versatile methodology provides an alternative approach for developing cancer nanovaccines. In situ vaccination is a desirable strategy for cancer immunotherapy due to its convenience and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic peptide with cholesterol‐modified, DP7‐C, for cancer immunotherapy is rationally designed, and developed a cancer nanovaccine that is easy to preparate. The nanovaccine includes cocktail small interfering RNAs (siRNAs) and immunologic adjuvant CpG ODNs, has synergistic effect in the cancer treatment. This nanovaccine can induce tumor cell death, promote antigen presentation and relieve immune suppression in the tumor microenvironment (TME). Moreover, this nanovaccine is administered to CT26 (hot) and B16F10 (cold) tumor model mice, in which it targeted the primary tumors and induced systemic antitumor immunity to inhibit metastasis. It is validated that the nanovaccine can convert cold tumors into hot tumors. Furthermore, the nanovaccine increased the immune response to anti‐PD‐1 therapy by modulating the TME in both CT26‐ and B16F10‐tumor‐bearing mice. The siRNA cocktail/CpG ODN/self‐assembling peptide nanovaccine is a simple and universal tool that can effectively generate specific tumor cell antigens and can be combined with immuno‐oncology agents to enhance antitumor immune activity. The versatile methodology provides an alternative approach for developing cancer nanovaccines.

Chitosan Nanoparticles Based Nanovaccines For Cancer Immunotherapy

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Nanovaccines: An effective therapeutic approach for cancer therapy

Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective

Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

Nanobiomaterial-based vaccination immunotherapy of cancer

Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine

In Situ Cocktail Nanovaccine for Cancer Immunotherapy

Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity

Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy

Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly As an Antitumor Vaccine.

Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy

Ultrasound Responsive Nanovaccine Armed with Engineered Cancer Cell Membrane and RNA to Prevent Foreseeable Metastasis

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

Polymer‐Protein Nanovaccine Synthesized via Reactive Self‐Assembly with Potential Application in Cancer Immunotherapy: Physicochemical And Biological Characterization In Vitro And in Vivo

Autologous-cancer-cryoablation-mediated Nanovaccine Augments Systematic Immunotherapy.

In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy

Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy